María José Vargas Contreras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
María José Vargas Contreras has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Jazmín Meneses Figueroa
Laboratory of Genetics, Faculty of Medicine, Autonomous University of the State of Mexico, Toluca, MEX
2 shared publications Hugo Mendieta Zerón
Faculty of Medicine, Autonomous University of the State of Mexico, Toluca, MEX
1 shared publication- Hugo Mendieta Zerón
Facultad de Medicina, Universidad Autónoma del Estado de México (UAEMéx), Toluca de Lerdo, Mexico
1 shared publication - Jesús Carlos Briones Garduño
Hospital «Mónica Pretelini Sáenz» Hospital General de México «Dr. Eduardo Liceaga» Unidad de Cuidados Intensivos Ciudad de México de la escala México
1 shared publication - José Anaya Herrera
Department of Obstetrics and Gynaecology, “Mónica Pretelini Sáenz” Maternal-Perinatal Hospital, Toluca, MEX
1 shared publication - José Antonio Mendoza López
Reseach and Teaching Unit, “Mónica Pretelini Sáenz” Maternal-Perinatal Hospital, Toluca, MEX
1 shared publication
Latest Publications
- Open Access
- 13 May 2021
- Published by Springer Nature in Cureus
- Vol. 13 (5)
Evolution of COVID-19 Pregnancies Treated With Nitazoxanide in a Third-Level Hospital
Nitazoxanide shows adequate in vitro activity against coronavirus. The aim of this study was to describe the behavior of coronavirus disease 2019 (COVID-19) in pregnant women treated with nitazoxanide. This cross-sectional study included the files of COVID-19 positive pregnant women treated with nitazoxanide 500 mg every 6 hours, levofloxacin every 12 hours, and clarithromycin 500 mg every 12 hours. The data of 51 women (mean age: 27.4 ± 7.2 years) were analyzed. Eleven (21.56%) patients had to receive medical attention in the intensive care unit. There were 22 (43.13%) preterm deliveries, 21 by cesarean and one by vaginal delivery. The medical attention of this population was as follows: 31 cesareans, five vaginal deliveries, nine still pregnant, two requiring manual vacuum aspiration, two ectopic pregnancies, one requiring curettage, and one requiring hysterotomy. There were seven (13.72%) cases of preeclampsia, and there were two (3.92%) deaths. Nitazoxanide prescription could be an option against COVID-19 in pregnancy due to its safety profile.
- 13 May 2021
- Published by Springer Nature in Cureus
- Vol. 13 (5)
Open AccessEvolution of COVID-19 Pregnancies Treated With Nitazoxanide in a Third-Level Hospital
Nitazoxanide shows adequate in vitro activity against coronavirus. The aim of this study was to describe the behavior of coronavirus disease 2019 (COVID-19) in pregnant women treated with nitazoxanide. This cross-sectional study included the files of COVID-19 positive pregnant women treated with nitazoxanide 500 mg every 6 hours, levofloxacin every 12 hours, and clarithromycin 500 mg every 12 hours. The data of 51 women (mean age: 27.4 ± 7.2 years) were analyzed. Eleven (21.56%) patients had to receive medical attention in the intensive care unit. There were 22 (43.13%) preterm deliveries, 21 by cesarean and one by vaginal delivery. The medical attention of this population was as follows: 31 cesareans, five vaginal deliveries, nine still pregnant, two requiring manual vacuum aspiration, two ectopic pregnancies, one requiring curettage, and one requiring hysterotomy. There were seven (13.72%) cases of preeclampsia, and there were two (3.92%) deaths. Nitazoxanide prescription could be an option against COVID-19 in pregnancy due to its safety profile.
- Open Access
- 30 September 2020
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 14 (09) , 982-986
Nitazoxanide against COVID-19 in three explorative scenarios
Introduction: Nitazoxanide has shown efficacy in vitro against coronavirus infections (MERS, SARS, SARS-CoV-2). The aim of this report is to describe the results of treating COVID-19 positive patients with nitazoxanide in three clinical settings: pregnancy/puerperium, hospitalized patients in an Internal Medicine Service and in an ambulatory setting. Methodology: This was a prospective follow-up and report of COVID-19 cases in three different situations, pregnant women, hospitalized patients receiving medical attention in an Internal Medicine Service and ambulatory patients residing in Toluca City, and Mexico City. Results: The experience with a first group of 20 women, pregnant (17) or in immediate puerperium (3) was successful in 18 cases with two unfortunate deaths. The five cases treated in an Internal Medicine service showed a positive outcome with two patients weaned from mechanical ventilation. Of the remaining 16 patients treated in an ambulatory setting, all got cured. Nitazoxanide seems to be useful against SARS-CoV-2, not only in an early intervention but also in critical condition as well as in pregnancy without undesired effects for the babies. As an adjunctive therapy budesonide was used that seems to contribute to the clinical improvement. Conclusions: Nitazoxanide could be useful against COVID-19 as a safe and available regimen to be tested in a massive way immediately.
- 30 September 2020
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 14 (09) , 982-986
Open AccessNitazoxanide against COVID-19 in three explorative scenarios
Introduction: Nitazoxanide has shown efficacy in vitro against coronavirus infections (MERS, SARS, SARS-CoV-2). The aim of this report is to describe the results of treating COVID-19 positive patients with nitazoxanide in three clinical settings: pregnancy/puerperium, hospitalized patients in an Internal Medicine Service and in an ambulatory setting. Methodology: This was a prospective follow-up and report of COVID-19 cases in three different situations, pregnant women, hospitalized patients receiving medical attention in an Internal Medicine Service and ambulatory patients residing in Toluca City, and Mexico City. Results: The experience with a first group of 20 women, pregnant (17) or in immediate puerperium (3) was successful in 18 cases with two unfortunate deaths. The five cases treated in an Internal Medicine service showed a positive outcome with two patients weaned from mechanical ventilation. Of the remaining 16 patients treated in an ambulatory setting, all got cured. Nitazoxanide seems to be useful against SARS-CoV-2, not only in an early intervention but also in critical condition as well as in pregnancy without undesired effects for the babies. As an adjunctive therapy budesonide was used that seems to contribute to the clinical improvement. Conclusions: Nitazoxanide could be useful against COVID-19 as a safe and available regimen to be tested in a massive way immediately.